Sarah Cherovsky, of Kewaunee, MI, will receive $2,500 for an education fund for her 10-month-old daughter, Erin. Ten honorable mention winners from around the country will each receive a $500 education fund.
About BRAVELLE and MENOPUR
BRAVELLE and MENOPUR, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8% respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.
The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE and/or MENOPUR may result in multiple gestations.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets BRAVELLE, MENOPUR, REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialists and their patients. Ferring also offers the Q.CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.
Ferring's line of orthopaedic and urology products includes
EUFLEXXA(TM), hyaluronic acid for pain from ost
|SOURCE Ferring Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved